> Erytech stopped developing eryaspase in acute lymphoblastic leukemia (ALL), wiping out a near-term commercial opportunity. The French biotech filed for EMA approval in the indication in 2015, only to withdraw it the following year. Erytech looked to be back on track when it refiled last year but recent talks with regulators suggest it will need to make additional, significant investments in the program to win approval. With ALL being a niche opportunity, Erytech has opted against making those investments. The decision sent Erytech’s stock into a multiday slide that wiped more than one-third off its market cap. Release
> Nordic Nanovector named Eduardo Bravo as its CEO. Bravo was last seen running TiGenix, which he led to a €520 million ($600 million) takeover by Takeda. Statement
> BerGenBio’s AXL inhibitor-Keytruda combination trial came through an early efficacy assessment. Release
> Inthera Bioscience secured the second, €4.7 million ($5.4 million) tranche of its series A round. Statement
> Five U.K. life science groups lobbied the government to change the tax relief benefits received by entrepreneurs. Release